INMED PHARMACEUTICALS INC. Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months
INMED PHARMACEUTICALS INC. (INM) had Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months of $96.47 thousand as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Rolling Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths · last filed 2021-05-13
- 2021-03-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $96.47K.
- 2020-12-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $96.47K.
- 2020-09-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $92.08K.
| Period end | Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months |
|---|---|
| 2021-03-31 | $96.47K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $96.47K 10-Q · filed 2021-02-11 |
| 2020-09-30 | $92.08K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |